Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/107318
DC FieldValueLanguage
dc.contributor.authorPires, N.-
dc.contributor.authorPinto, P. G. N.-
dc.contributor.authorMarçal, N-
dc.contributor.authorFerreira, A. J.-
dc.contributor.authorRodrigues, C. M. P.-
dc.contributor.authorBárbara, C-
dc.date.accessioned2023-07-03T10:20:53Z-
dc.date.available2023-07-03T10:20:53Z-
dc.date.issued2019-
dc.identifier.issn25310437pt
dc.identifier.urihttps://hdl.handle.net/10316/107318-
dc.description.abstractChronic Obstructive Pulmonary Disease (COPD) is currently the 4th leading cause of death worldwide but is projected to be the 3rd leading cause of death by 2020. In Portugal, the estimated prevalence of COPD in the Lisbon region is 14.2%, and a large proportion of underdiagnosed disease has been detected. In 2016, a Portuguese panel of experts proposed pharmacological treatment approaches to COPD based on the evidence available at the time. However, given that the GOLD 2017 report introduced considerable changes to the 2016 version, and that new evidence has emerged regarding treatment options, these proposals need to be updated. Also, and based on several studies, the concept of Pre-GOLD patients, which has diagnostic, prognostic and therapeutic implications, is introduced, along with a proposed algorithm for the identification and treatment of these patients.pt
dc.language.isoengpt
dc.publisherElsevierpt
dc.relationNovartis Portugalpt
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt
dc.subjectFLAMEpt
dc.subjectPre-GOLD patientspt
dc.subjectDiagnosispt
dc.subjectAlgorithmpt
dc.subject.meshAdministration, Inhalationpt
dc.subject.meshAlgorithmspt
dc.subject.meshBronchodilator Agentspt
dc.subject.meshDisease Progressionpt
dc.subject.meshDrug Combinationspt
dc.subject.meshFluticasone-Salmeterol Drug Combinationpt
dc.subject.meshForced Expiratory Volumept
dc.subject.meshGlycopyrrolatept
dc.subject.meshHumanspt
dc.subject.meshIndanspt
dc.subject.meshPortugalpt
dc.subject.meshPrevalencept
dc.subject.meshPrognosispt
dc.subject.meshPulmonary Disease, Chronic Obstructivept
dc.subject.meshQuinolonespt
dc.subject.meshRisk Factorspt
dc.subject.meshSeverity of Illness Indexpt
dc.titlePharmacological treatment of COPD - New evidencept
dc.typearticle-
degois.publication.firstPage90pt
degois.publication.lastPage96pt
degois.publication.issue2pt
degois.publication.titlePulmonologypt
dc.peerreviewedyespt
dc.identifier.doi10.1016/j.pulmoe.2018.10.005pt
degois.publication.volume25pt
dc.date.embargo2019-01-01*
uc.date.periodoEmbargo0pt
item.grantfulltextopen-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.openairetypearticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextCom Texto completo-
crisitem.author.orcid0000-0002-1016-977X-
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais
Files in This Item:
File Description SizeFormat
Pharmacological treatment of COPD – New evidence.pdf677.11 kBAdobe PDFView/Open
Show simple item record

SCOPUSTM   
Citations

10
checked on May 6, 2024

WEB OF SCIENCETM
Citations

9
checked on May 2, 2024

Page view(s)

35
checked on May 7, 2024

Download(s)

15
checked on May 7, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons